The Peptide Boom: What Telehealth Businesses Need to Know About Peptides, LegitScript and Payment Processing
Updated: Oct 6
Peptides have become one of the fastest-growing areas of the telehealth, weight-loss, longevity and wellness markets.
Search online or scroll through social media and you'll encounter names such as retatrutide, BPC-157, TB-500, injectable GHK-Cu, MOTS-C, CJC-1295, ipamorelin, Semax, Selank, tesamorelin and cagrilintide—often accompanied by claims involving weight loss, anti-aging, recovery, metabolic health and athletic performance.
Consumer demand is substantial, and entrepreneurs, telemedicine providers, physician groups, pharmacies and e-commerce businesses understandably want to participate in that growth.
But there is another side to the peptide boom that every healthcare business should understand:
Regulatory compliance and payment processing are increasingly interconnected.
A product being widely advertised online does not necessarily mean that it can legally be prescribed, compounded, marketed or sold under the regulatory framework that applies to a particular business.
And for telehealth and healthcare merchants, those questions can directly affect LegitScript certification, acquiring-bank underwriting, merchant account approval and the long-term stability of payment processing.
Popular Doesn't Necessarily Mean Permissible
One of the biggest misconceptions in the peptide industry is that widespread availability means a product is permissible. It doesn't.
Several heavily marketed peptides remain unapproved or otherwise do not currently qualify for the applicable compounding pathways.
This includes products attracting significant consumer attention such as retatrutide, BPC-157, TB-500 and cagrilintide.
The regulatory circumstances are not identical for every peptide.
Some substances have been considered by the FDA's Pharmacy Compounding Advisory Committee (PCAC) as part of the process surrounding the Section 503A Bulk Drug Substances List.
Others, including investigational drugs such as retatrutide and cagrilintide, remain in clinical development.
An important distinction for healthcare businesses is that an FDA advisory committee recommendation does not by itself authorize compounding or change a substance's legal status.
Regulatory changes generally require additional FDA action and, where applicable, formal rulemaking.
Until such changes actually take effect, businesses need to operate under the requirements currently in force.
503A and 503B Compounding Matter
For businesses operating in the compounded-medication market, understanding the distinction between 503A pharmacies and 503B outsourcing facilities is important.
For a bulk drug substance to qualify for compounding under the applicable 503A framework, it generally must satisfy an applicable statutory pathway, such as inclusion on the relevant FDA bulk-drug-substances list, being covered by an applicable USP or National Formulary monograph, or being a component of an FDA-approved drug.
503B outsourcing facilities operate under a separate framework and face their own restrictions.
This is one reason a telehealth company shouldn't assume that because a product appears elsewhere in the market, its own physicians, pharmacy partners or fulfillment operation can automatically offer it.
The details matter.
LegitScript Certification and Peptide Businesses
For many telemedicine and online healthcare companies, LegitScript certification has become an important part of operating online.
Certification can matter when businesses want to advertise through major digital platforms, establish relationships with vendors and demonstrate that their healthcare operations meet applicable standards.
LegitScript evaluates businesses based on its certification standards and applicable laws and regulations—not on where a particular segment of the healthcare industry hopes regulations will eventually go.
That distinction becomes especially important with peptides. A compliance problem may involve more than physically dispensing a product.
Depending on the circumstances, concerns can arise from:
Offering or promoting an impermissible product
Advertising an unapproved drug
Making unsupported efficacy or safety claims
Providing dosing recommendations for unapproved products
Suggesting an investigational product is FDA-approved
Using another entity to prescribe or dispense a problematic product as part of the same continuum of care
For telehealth businesses seeking LegitScript certification, compliance therefore needs to be considered across the entire patient journey.
That can include the website, advertising, physician relationship, pharmacy relationship, product claims, checkout process and fulfillment model.
Educational Content vs. Peptide Promotion
Content marketing has become particularly complicated for peptide businesses.
There is an important difference between publishing educational information about an investigational or unapproved substance and actively encouraging consumers to obtain or use it.
An educational article might discuss:
What is retatrutide?
or:
What is the current FDA status of BPC-157?
That is very different from publishing claims such as:
"Buy BPC-157 to heal injuries faster."
Educational content should remain factual and balanced, explain the regulatory status of the substance and avoid presenting unproven claims as established medical facts.
Healthcare companies should be especially careful with claims that a peptide is "clinically proven," "safe," "FDA approved," capable of "healing" a particular condition or otherwise proven effective when the available evidence and regulatory status do not support those statements.
This isn't only an SEO or advertising issue.
It can become a merchant-processing issue as well.
Why Peptide Compliance Matters to Payment Processors
Healthcare payment processing isn't the same as opening a conventional merchant account for a restaurant or retail store.
Telehealth, online pharmacies, compounded medications, GLP-1 programs, HRT and peptide businesses can receive additional scrutiny from processors, acquiring banks and their compliance teams.
An underwriter may want to understand:
What products are being sold?
Who is prescribing them?
Which pharmacy is dispensing them?
Is a valid prescription required?
Is the pharmacy properly licensed?
In which states does the business operate?
What claims appear on the website?
Does the merchant have required certifications?
How are recurring payments handled?
What is the expected monthly processing volume?
What is the average transaction size?
What are the refund and chargeback policies?
Does the website accurately represent the business model submitted for underwriting?
This means the merchant account application shouldn't be treated as an isolated financial application.
Your website, compliance structure, prescribing model, pharmacy relationships and payment processing all need to tell the same story.
Stripe vs. a Bank-Direct Merchant Account
Many healthcare startups begin accepting payments using platforms such as Stripe because implementation can be fast and relatively simple.
As the business grows, however, management may want to evaluate whether its payment infrastructure still fits the company's risk profile, transaction volume and operational requirements.
This is where a bank-direct merchant account can be worth considering.
At GreenPayment and BLVD Merchant Group, we work with businesses to evaluate payment-processing structures based on their particular business model.
For qualified healthcare merchants, potential considerations can include:
Transparent processing statements.
Businesses can more clearly understand interchange, processor markup and other processing costs.
Underwriting based on the actual business model.
A healthcare merchant should be properly represented and reviewed rather than trying to disguise what it sells.
Funding and cash-flow planning.
Growing healthcare businesses need predictable access to revenue for marketing, pharmacy obligations, payroll and operating expenses.
Scalability.
A company processing $50,000 per month has different requirements from a telehealth platform processing $500,000, $2 million or more per month.
Gateway and technology integrations.
Depending on the merchant and underwriting approval, payment infrastructure can include established gateways and integrations designed around the company's checkout and technology stack.
ACH and alternative payment options.
For appropriate merchants, bank-account payment options may complement conventional credit and debit card acceptance.
Most importantly, healthcare merchants should seek a processing relationship where the provider understands what the company actually does.
Don't Hide the Peptide Business From Your Processor
One of the most dangerous approaches a telehealth or peptide company can take is attempting to obtain processing by describing itself as something materially different from its actual business.
A merchant selling or facilitating healthcare products shouldn't present itself simply as a generic "wellness company" if that description omits material facts necessary for underwriting.
That can create problems later.
The better approach is to establish a processing structure based on transparent underwriting of the real business model.
Before submitting a healthcare merchant for underwriting, GreenPayment / BLVD Merchant Group can work to understand the company's website, products, prescribing model, pharmacy relationships, certifications, expected processing volume and existing payment environment.
The objective isn't merely to obtain an approval.
The objective is to build a payment-processing relationship designed to remain stable as the business grows.
LegitScript, Telehealth and Merchant Processing Should Be Considered Together
For entrepreneurs entering telehealth, peptides, compounded medications, weight loss, GLP-1 programs or hormone-replacement therapy, compliance is sometimes addressed only after the website and marketing funnel have already been built.
That can become expensive.
A better sequence is to consider:
Business Model → Regulatory/Legal Review → Website Compliance → Medical & Pharmacy Relationships → LegitScript Requirements → Merchant Underwriting → Payment Gateway → Marketing & Customer Acquisition
Getting those components aligned early can reduce the likelihood of having to rebuild websites, change advertising language, replace vendors or search for new payment processing after launch.
Already Processing? Review Your Merchant Statements
Established telehealth companies should also periodically review their existing payment-processing arrangement.
GreenPayment / BLVD Merchant Group can perform an apples-to-apples merchant statement analysis using the business's recent processing statements.
The analysis can examine items such as:
Effective processing rate
Interchange costs
Processor markup
Transaction fees
Gateway fees
Monthly and miscellaneous fees
Funding schedule
Chargeback considerations
ACH opportunities
Potential alternative processing structures
For a healthcare business processing hundreds of thousands—or millions—of dollars per month, relatively small differences in the effective processing rate can translate into substantial annual costs.
The Future of Peptides
The peptide market will continue to evolve.
Clinical trials will progress. FDA policies may change. Compounding rules may change. New medications may receive approval, and healthcare businesses will continue developing new ways of delivering treatment online.
But businesses shouldn't build today's operation around what regulations might permit tomorrow.
They need to operate according to the requirements applicable today and adapt as the regulatory environment changes.
The same principle applies to payment processing.
It needs a payment infrastructure built around the company's actual products, compliance requirements, transaction volume and growth strategy.
Payment Processing for Telehealth, Peptides, GLP-1 and Online Healthcare
GreenPayment and BLVD Merchant Group work with healthcare and e-commerce businesses seeking payment-processing solutions, including companies operating in areas such as:
Telemedicine • Online Healthcare • Online Pharmacies • Compounded Medications • GLP-1 Weight-Loss Programs • HRT • Men's Health • Women's Health • Wellness • Peptide Businesses • Subscription Healthcare
If you're launching a healthcare business, preparing for LegitScript certification, reconsidering your current processor or currently using Stripe and want to compare your options, we can review your business model and payment requirements.
Already processing substantial volume?
Provide two to three recent merchant-processing statements, and Green Payment can prepare an apples-to-apples comparison of your current processing costs and structure.
GreenPayment / BLVD Merchant Group
Payment Processing for Telehealth & Online Healthcare
This article is provided for general informational purposes and should not be considered legal, regulatory or medical advice. Regulatory status, compounding requirements, certification standards and payment-processing eligibility can change. Healthcare businesses should obtain advice from qualified legal and compliance professionals regarding their specific operations.